Cannabis & Autism
$49.00
This curriculum was developed in 2021 and reflects the scientific and clinical understanding available at that time. As this field continues to advance, we are preparing a comprehensive curriculum update incorporating the latest research and best practices. The new program is expected to launch in Q4 2026. Subscribe to receive updates and early access information.
Patricia Frye, MD details how both core and coexisting conditions associated with Autistic Spectrum Disorder (ASD) may improve with cannabis medicine. The course also addresses the limitations of pharmaceuticals that are currently FDA approved for autism as well as those that are commonly used but based on anecdotal evidence. Dr. Frye reviews approaches to chemovar profiles, dosing regimens and special considerations when treating ASD in children and young adults.
*Includes a certificate of completion
